Atara Biotherapeutics, Inc. – NASDAQ:ATRA

Atara Biotherapeutics stock price today

$12
-0.15
-1.24%
Financial Health
0
1
2
3
4
5
6
7
8
9

Atara Biotherapeutics stock price monthly change

+16.05%
month

Atara Biotherapeutics stock price quarterly change

+16.05%
quarter

Atara Biotherapeutics stock price yearly change

+2070.03%
year

Atara Biotherapeutics key metrics

Market Cap
67.38M
Enterprise value
229.27M
P/E
-1.16
EV/Sales
3.61
EV/EBITDA
-1.04
Price/Sales
4.16
Price/Book
2.08
PEG ratio
-0.03
EPS
-2.13
Revenue
34.70M
EBITDA
-212.91M
Income
-233.10M
Revenue Q/Q
2131.40%
Revenue Y/Y
-39.62%
Profit margin
-360.37%
Oper. margin
-442.78%
Gross margin
81.42%
EBIT margin
-442.78%
EBITDA margin
-613.52%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Atara Biotherapeutics stock price history

Atara Biotherapeutics stock forecast

Atara Biotherapeutics financial statements

Average Price Target
Last Year

$14

Potential upside: 16.66%

Based on estimate of 2 analysts
  • Analysts Price target

  • Financials & Ratios estimates

Atara Biotherapeutics, Inc. (NASDAQ:ATRA): Profit margin
Jun 2023 957K -71.10M -7430.3%
Sep 2023 2.13M -69.79M -3264.59%
Dec 2023 4.25M -60.45M -1421.68%
Mar 2024 27.35M -31.75M -116.07%
Atara Biotherapeutics, Inc. (NASDAQ:ATRA): Debt to assets
Jun 2023 246439000 238.98M 96.98%
Sep 2023 188788000 239.62M 126.93%
Dec 2023 165504000 264.73M 159.96%
Mar 2024 165272000 263.57M 159.48%
Atara Biotherapeutics, Inc. (NASDAQ:ATRA): Cash Flow
Jun 2023 -52.79M 49.48M 471K
Sep 2023 -51.34M 70.44M -208K
Dec 2023 -50.40M 9.94M 1.51M
Mar 2024 -29.61M 14.71M 24.14M

Atara Biotherapeutics alternative data

Atara Biotherapeutics, Inc. (NASDAQ:ATRA): Employee count
Aug 2023 330
Sep 2023 317
Oct 2023 317
Nov 2023 317
Dec 2023 334
Jan 2024 334
Feb 2024 334
Mar 2024 334
Apr 2024 334
May 2024 225
Jun 2024 173
Jul 2024 173

Atara Biotherapeutics other data

53.26% -41.78%
of ATRA is owned by hedge funds
54.32M -43.02M
shares is hold by hedge funds

Atara Biotherapeutics, Inc. (NASDAQ:ATRA): Insider trades (number of shares)
Period Buy Sel
Mar 2024 0 56192
May 2024 0 211204
Aug 2024 0 8050
Nov 2024 0 4028
Transaction Date Insider Security Shares Price per share Total value Source
Sale
HENRICH JILL officer: EVP, Chief Regulatory ..
Common Stock 1,000 $11.2 $11,198
Sale
HYLLENGREN ERIC J officer: EVP, CFO and COO
Common Stock 1,364 $11.2 $15,274
Sale
NGUYEN ANHCO director, officer: President an..
Common Stock 1,664 $11.2 $18,633
Sale
TOUCHON PASCAL director, officer: President an..
Common Stock 2,762 $6.63 $18,309
Sale
TOUCHON PASCAL director, officer: President an..
Common Stock 276 $6.63 $1,830
Sale
NGUYEN ANHCO officer: EVP, Chief Sci. & Tech..
Common Stock 1,468 $6.63 $9,731
Sale
NGUYEN ANHCO officer: EVP, Chief Sci. & Tech..
Common Stock 297 $6.63 $1,969
Sale
NGUYEN ANHCO officer: EVP, Chief Sci. & Tech..
Common Stock 56 $6.63 $371
Sale
MURUGAN AMAR officer: EVP, Chi.. Common Stock 877 $6.63 $5,814
Sale
MURUGAN AMAR officer: EVP, Chi.. Common Stock 192 $6.63 $1,273
Insider Compensation
Dr. Pascal Touchon D.V.M. (1963) Pres, Chief Executive Officer & Director
$1,090,000
Dr. Kristin Yarema Ph.D. (1971) SVice President & Chief Commercial Officer $700,670
Mr. Joseph Newell (1970) Executive Vice President & Chief Operating Officer
$670,380
Mr. Utpal Koppikar (1971) Chief Financial Officer & SVice President $655,450
Dr. Jakob Dupont (1965) Head of Global R&D $595,870
Wednesday, 27 November 2024
businesswire.com
Wednesday, 13 November 2024
businesswire.com
Tuesday, 12 November 2024
zacks.com
businesswire.com
Tuesday, 15 October 2024
zacks.com
Friday, 4 October 2024
businesswire.com
Monday, 12 August 2024
zacks.com
businesswire.com
Monday, 15 July 2024
zacks.com
Friday, 5 July 2024
businesswire.com
Wednesday, 3 July 2024
businesswire.com
seekingalpha.com
Friday, 21 June 2024
businesswire.com
Monday, 17 June 2024
businesswire.com
Friday, 7 June 2024
businesswire.com
Wednesday, 5 June 2024
businesswire.com
Wednesday, 29 May 2024
businesswire.com
Monday, 20 May 2024
businesswire.com
Thursday, 9 May 2024
Zacks Investment Research
Thursday, 28 March 2024
Zacks Investment Research
Monday, 5 February 2024
Seeking Alpha
Thursday, 4 January 2024
Business Wire
Wednesday, 29 November 2023
Business Wire
Wednesday, 22 November 2023
PennyStocks
Friday, 17 November 2023
PennyStocks
Wednesday, 15 November 2023
PennyStocks
Monday, 13 November 2023
Seeking Alpha
Saturday, 4 November 2023
Seeking Alpha
Thursday, 21 September 2023
Zacks Investment Research
Tuesday, 8 August 2023
Zacks Investment Research
  • What's the price of Atara Biotherapeutics stock today?

    One share of Atara Biotherapeutics stock can currently be purchased for approximately $12.

  • When is Atara Biotherapeutics's next earnings date?

    Unfortunately, Atara Biotherapeutics's (ATRA) next earnings date is currently unknown.

  • Does Atara Biotherapeutics pay dividends?

    No, Atara Biotherapeutics does not pay dividends.

  • How much money does Atara Biotherapeutics make?

    Atara Biotherapeutics has a market capitalization of 67.38M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 86.51% to 8.57M US dollars.

  • What is Atara Biotherapeutics's stock symbol?

    Atara Biotherapeutics, Inc. is traded on the NASDAQ under the ticker symbol "ATRA".

  • What is Atara Biotherapeutics's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Atara Biotherapeutics?

    Shares of Atara Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Atara Biotherapeutics's key executives?

    Atara Biotherapeutics's management team includes the following people:

    • Dr. Pascal Touchon D.V.M. Pres, Chief Executive Officer & Director(age: 62, pay: $1,090,000)
    • Dr. Kristin Yarema Ph.D. SVice President & Chief Commercial Officer(age: 54, pay: $700,670)
    • Mr. Joseph Newell Executive Vice President & Chief Operating Officer(age: 55, pay: $670,380)
    • Mr. Utpal Koppikar Chief Financial Officer & SVice President(age: 54, pay: $655,450)
    • Dr. Jakob Dupont Head of Global R&D(age: 60, pay: $595,870)
  • How many employees does Atara Biotherapeutics have?

    As Jul 2024, Atara Biotherapeutics employs 173 workers, which is 48% less then previous quarter.

  • When Atara Biotherapeutics went public?

    Atara Biotherapeutics, Inc. is publicly traded company for more then 10 years since IPO on 16 Oct 2014.

  • What is Atara Biotherapeutics's official website?

    The official website for Atara Biotherapeutics is atarabio.com.

  • Where are Atara Biotherapeutics's headquarters?

    Atara Biotherapeutics is headquartered at 611 Gateway Boulevard, South San Francisco, CA.

  • How can i contact Atara Biotherapeutics?

    Atara Biotherapeutics's mailing address is 611 Gateway Boulevard, South San Francisco, CA and company can be reached via phone at +65 02788930.

  • What is Atara Biotherapeutics stock forecast & price target?

    Based on 2 Wall Street analysts` predicted price targets for Atara Biotherapeutics in the last 12 months, the avarage price target is $14. The average price target represents a 16.66% change from the last price of $12.

Atara Biotherapeutics company profile:

Atara Biotherapeutics, Inc.

atarabio.com
Exchange:

NASDAQ

Full time employees:

165

Industry:

Biotechnology

Sector:

Healthcare

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

611 Gateway Boulevard
South San Francisco, CA 94080

CIK: 0001604464
ISIN: US0465131078
CUSIP: 046513107